文献速递MDS 与骨髓增殖性肿瘤

骨髓增殖性肿瘤的遗传基础与分子图谱

Genetic basis and molecular profiling in myeloproliferative neoplasms.
PubMed 文献 · Blood · 2023-01-01

本文综述了BCR::ABL1阴性骨髓增殖性肿瘤(MPN)的遗传基础与分子特征。获得性功能获得性驱动基因突变(JAK2、CALR、MPL)即可启动MPN,JAK2-p.V617F见于>95%的真性红细胞增多症(PV)患者及约半数原发性血小板增多症(ET)或原发性骨髓纤维化(PMF)患者。克隆扩增而非驱动突变获得是决定MPN发病频率的限制因素,遗传易感性、额外突变和炎症控制克隆性造血向MPN的转化。

要点

  • JAK2-p.V617F见于>95%的PV患者及约半数ET或PMF患者。
  • 约10%的MPN患者为「三阴性」,未检测到已知驱动基因突变。
  • 驱动突变与三阴性MPN的共同主题是JAK/STAT信号通路组成性激活。

核心结论

  • MPN的三个驱动基因突变与三阴性MPN的共同主题是Janus激酶-信号转导及转录激活因子(JAK/STAT)信号通路组成性激活。
  • 决定MPN以长潜伏期发病频率的限制因素不是驱动基因突变的获得,而是克隆的扩增。
  • 控制克隆性造血向MPN转化的因素包括遗传易感性、额外突变的存在和炎症。

研究设计与样本

  • 综述,回顾近期关于驱动基因突变获得后早期事件的认识进展。

主要发现

  • JAK2-p.V617F存在于>95%的PV患者中,也存在于约半数ET或PMF患者中。
  • ET和PMF也可由CALR或MPL突变引起。
  • 约10%的MPN患者为「三阴性」,未检测到任何已知驱动基因突变。

关键数值与推荐

  • PV、ET和PMF三种亚型根据世界卫生组织(WHO)和国际共识分类(ICC)标准诊断。
  • JAK2、CALR和MPL三个驱动基因中任一个的获得性功能获得性突变是致病事件,无需额外协同突变即可单独启动和促进MPN疾病。

临床怎么用

  • 目前已越来越多地利用个体MPN患者突变图谱的全面知识来预测结局和选择最佳治疗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BCR::ABL1-negative myeloproliferative neoplasms (MPNs) are clonal diseases originating from a single hematopoietic stem cell that cause excessive production of mature blood cells. The 3 subtypes, that is, polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), are diagnosed according to the World Health Organization (WHO) and international consensus classification (ICC) criteria. Acquired gain-of-function mutations in 1 of 3 disease driver genes (JAK2, CALR, and MPL) are the causative events that can alone initiate and promote MPN disease without requiring additional cooperating mutations. JAK2-p.V617F is present in >95% of PV patients, and also in about half of the patients with ET or PMF. ET and PMF are also caused by mutations in CALR or MPL. In ∼10% of MPN patients, those referred to as being "triple negative," none of the known driver gene mutations can be detected. The common theme between the 3 driver gene mutations and triple-negative MPN is that the Janus kinase-signal transducer and activator of transcription (JAK/STAT) signaling pathway is constitutively activated. We review the recent advances in our understanding of the early events after the acquisition of a driver gene mutation. The limiting factor that determines the frequency at which MPN disease develops with a long latency is not the acquisition of driver gene mutations, but rather the expansion of the clone. Factors that control the conversion from clonal hematopoiesis to MPN disease include inherited predisposition, presence of additional mutations, and inflammation. The full extent of knowledge of the mutational landscape in individual MPN patients is now increasingly being used to predict outcome and chose the optimal therapy.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Luque Paz D, Kralovics R, Skoda RC, et al. Genetic basis and molecular profiling in myeloproliferative neoplasms. Blood. 2023. PMID: 36347013. doi:10.1182/blood.2022017578

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。